Helogen Corporation — CELS Autonomous Orbital Biology Lab¶
Space biology company with flight heritage, building autonomous orbital laboratories for biomanufacturing
Created: Session 74 (2026-04-07)
Last updated: Session 74 (2026-04-07)
Company Profile¶
| Field | Value |
|---|---|
| Location | New York, NY |
| Type | Space biology / in-space manufacturing startup |
| Former name | Odyssey SpaceWorks Corp |
| Founded | ~2020 (incorporated NY) |
| CEO/Founder | Shishir Bankapur |
| PI on FO | Caitlin Golden |
| Co-I on FO | Jacob Soccimerra |
| Funding raised | $2.78M |
| Investors | AUM Ventures, Aurelia Foundry, One Way Ventures |
| First launch | 2023 |
This is NOT an early-stage TechLeap winner. Helogen (formerly Odyssey SpaceWorks) is a space biology and infrastructure company that has already achieved first-ever autonomous genomic sequencing in orbit, has multiple scheduled missions, international partnerships (Starlab, AgResearch), and a recent acquisition (Vellon Space). The TechLeap Prize and FO project add NASA-funded flight testing to an already-active commercial pipeline.
HEL-IOS™ (Helogen Orbital Biomedical Operating System) is their core platform — the "world's first orbital biomedical operating system." It enables fully autonomous, regulatory-grade manufacturing of high-value biomaterials in orbit, integrating biological cultivation, processing, sequencing, and in-line analytics into a single closed-loop system without crew intervention.
FO Project¶
184150 — Cellular Experiment Laboratory System (CELS)¶
- Status: Active (Jun 2025 – Jun 2027)
- TRL: 3 → 5 (target)
- TX: TX06.3.1: Medical Diagnosis and Prognosis
- Destination: Foundational Knowledge, Others Inside the Solar System
- Flight: Suborbital (TechLeap Prize, 2026)
Technology: CELS enables autonomous, in-situ cell-based experiments including organoids and microphysiological systems (organ-on-chip). Core capabilities: - Microfluidic systems for sample handling and mixing - Spectrophotometry and imaging for downstream analysis - Automated cell culturing, treatment delivery, and analysis - No manual intervention or downmass required - Designed for integration into free-flying satellites, hosted flights, and space stations
Mission context: CELS reduces reliance on ISS scheduling, astronaut intervention, and sample return. Helogen claims autonomous labs can complete research projects in ~3 months vs. 18-36 months via traditional ISS pathways.
TechLeap Prize winner — selected from 200+ applicants for up to $500K + flight test opportunity.
TechPort Footprint¶
| Project | Program | Role | Period | Notes |
|---|---|---|---|---|
| 184150 | FO | Lead | 2025–2027 | CELS organ-on-chip |
Single TechPort project. Despite active commercial operations and flight heritage, Helogen's broader work is not in TechPort — it exists entirely in the commercial space biology ecosystem outside NASA's STMD programs.
Funding¶
Government funding¶
No USASpending contracts found under "Helogen Corporation" or "Odyssey SpaceWorks." The $500K TechLeap Prize is their first identified NASA funding.
Venture funding¶
- Total raised: $2.78M (per PitchBook)
- Investors: AUM Ventures, Aurelia Foundry, One Way Ventures
- Most recent: Merger/Acquisition of Vellon Space (Apr 30, 2025)
This is light funding compared to competitors like Varda ($329M) but consistent with Helogen's lean autonomous-lab approach.
Missions & Operations¶
| Mission | Date | Type | Focus |
|---|---|---|---|
| First launch | 2023 | Orbital | First autonomous genomic sequencing in orbit |
| HC-252-Conan | Nov 2025 | Drug Development | Radiation mitigation and oncology |
| HC-263-Cyrus | Mar 2026 | Life Sciences | High-throughput screening, in-space manufacturing |
| HC-264-TBD | Jun 2026 | Life Sciences | TBD |
Note: Mission details from company sources; independent verification of the "first autonomous genomic sequencing in orbit" claim not confirmed via NASA or third-party sources. This warrants verification.
Partnerships & Acquisitions¶
Starlab Space / Voyager Technologies (Feb 2026)¶
HEL-IOS™ will be integrated into the Starlab space station to enable continuous, autonomous biological discovery in LEO. This is a significant commercial anchor — Starlab is Voyager Technologies' post-ISS commercial station.
AgResearch Partnership (Apr 2025)¶
Partnership with AgResearch, a New Zealand Crown Research Institute, to develop bacterial nanocellulose (BNC) manufacturing in space using Helogen's autonomous orbital labs.
Vellon Space Acquisition (Apr 2025)¶
Acquired Vellon Space Private Limited (Bengaluru, India), a startup specializing in unmanned space laboratories and microgravity research. This expands Helogen's reach into India's space and biotech sectors.
Upstream Lineage¶
- No prior NASA lineage. Helogen emerged from the commercial space biology ecosystem, not from NASA SBIR/STTR or university research
- Incorporated as Odyssey SpaceWorks Corp in New York, rebranded to Helogen Corporation
- Founder trajectory: Shishir Bankapur — details on prior experience limited in public sources
Downstream Potential¶
- Starlab integration: Permanent presence on post-ISS commercial LEO station — long-term revenue stream
- Pharmaceutical/cosmetics customers: Description mentions cancer radiation studies, accelerated aging research, new cosmetics molecules
- In-space biomanufacturing market: Competes with Varda Space Industries (reentry manufacturing), Redwire (ISS-based), Space Tango (ISS-based)
- International expansion: India (Vellon Space) and New Zealand (AgResearch) partnerships extend addressable market
- Platform flexibility: CELS modular design supports suborbital, orbital, commercial station, and CLPS use cases
Assessment¶
| Dimension | Rating |
|---|---|
| Technology readiness | Mid-stage (flight heritage from 2023, autonomous sequencing demonstrated) |
| Funding trajectory | Early venture ($2.78M) — lean but active |
| Commercial traction | Strong — 3+ missions, Starlab partnership, international expansion |
| Downstream impact | Active (already generating commercial partnerships and missions) |
| Confidence | Suggestive — claimed achievements credible but independently unverified |
Time dimension: Founded ~2020 as Odyssey SpaceWorks. First launch 2023. Rebranded to Helogen. TechLeap Prize Jun 2025. FO project 2025-2027. Vellon acquisition Apr 2025. AgResearch partnership Apr 2025. Starlab partnership Feb 2026. This company has been executing for 3+ years before entering FO.
Key insight: Helogen is the most commercially advanced of all 10 TechLeap Space Technology Payload Challenge winners. Unlike the other winners (which are early-stage university spinouts or first-time space ventures), Helogen already has orbital flight heritage, multiple scheduled missions, international partnerships, and a post-ISS station integration deal. The FO/TechLeap project adds NASA validation and suborbital testing, but CELS is an incremental addition to an already-active commercial program.
Comparison to Ambrosia Space: Both are in the in-space biomanufacturing space (both FO TechLeap winners, both TX06.3.1). Ambrosia is pre-revenue with $179K total funding; Helogen has $2.78M raised, flight heritage, and Starlab integration. Helogen is ~3-4 years ahead.
Open Questions¶
- What platform/vehicle carried Helogen's 2023 orbital mission? (Company claims not independently verified)
- Is Caitlin Golden a Helogen employee or academic collaborator? Her role as PI suggests technical leadership
- What is the revenue model — does Helogen sell data, materials, or lab-time-as-a-service?
- How does the $2.78M funding sustain multiple orbital missions? Are missions revenue-positive via customer payments?
- What happened to the "Conan" mission (Nov 2025)? Did it fly? Results?
Sources: TechPort 184150; NASA TechLeap Prize; Helogen website; Factories in Space; GlobeNewsWire (Vellon Space acquisition, AgResearch partnership); Voyager Technologies (Starlab partnership); PitchBook; Crunchbase; BizProfile.net